IgD型多发性骨髓瘤新药时代下的预后及治疗进展  

Prognosis and treatment progress of IgD multiple myeloma in the era of new drugs

作　　者：吴涛[1] 刘文慧 Wu Tao;Liu Wen-hui(Department of Hematology,The 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army,Lanzhou 730050,China)

机构地区：[1]中国人民解放军联勤保障部队第九四○医院血液科/全军血液病中心,甘肃兰州730050

出　　处：《兰州大学学报（医学版）》2022年第12期74-78,共5页Journal of Lanzhou University（Medical Sciences）

基　　金：甘肃省创新基地和人才计划(甘肃省白血病临床研究中心)资助项目(21JR7RA015)。

摘　　要：多发性骨髓瘤(MM)为克隆性浆细胞的恶性增殖,能够产生单克隆免疫球蛋白或其片段(M蛋白),从而引起相关组织和器官的损害。免疫球蛋白D(IgD)型MM在临床较罕见,国外报道约占所有MM患者的1%~2%,国内报道为3%~8.9%,较其他类型MM侵袭性更高,预后不良。其特征是好发于中老年男性,λ轻链型多见,表现为难治、复发,临床仍无法治愈。目前关于IgD型MM在临床尚无大量研究数据,本研究就IgD型MM的临床特征、预后因素及新药时代下的治疗进展进行综述。Multiple myeloma(MM)is defined as malignant proliferation of clonal plasma cells,which can produce monoclonal immunoglobulins or their fragments(M proteins)and cause damage to related tissues and organs.Immunoglobulin D(IgD)MM is rare in clinical practice,accounting for about 1%~2%of all MM patients in abroad reports and 3%~8.9%in domestic reports,which is more invasive and has a poor prognosis than other types of MM.It is characterized by a predilection for in middle-aged men,λlight chain type is more common,manifested as refractory,relapse,and remains incurable in clinical practice.At present,there is no large amount of research data on IgD MM in clinical practice.This article reviews the clinical characteristics,prognostic factors and treatment progress of IgD MM in the era of new drugs.

关 键 词：免疫球蛋白D 多发性骨髓瘤 新药时代 预后 

分 类 号：R733.3[医药卫生—肿瘤]